Skip to main content
. 2021 Nov 16;41(4):550–559. doi: 10.1038/s41388-021-02088-7

Fig. 1. Cathepsin K inhibition sensitizes oxaliplatin-mediated apoptosis.

Fig. 1

A–E Cancer or normal cell lines were treated with a 25 μM oxaliplatin or/and 2 μM odanacatib (ODN) for 24 h. Quantification of DNA fragments was determined using a DNA fragmentation assay kit (D). Detection of caspase activity was measured using a DEVDase colorimetric assay kit (E). F Caki-1 cells were treated with a combination of 2 μM ODN and 25 μM oxaliplatin in the presence or absence of a pan-caspase inhibitor, 20 μM z-VAD-fmk (z-VAD), for 24 h. G, H Caki-1 cells were treated with a combination of 2 μM ODN and 25 μM oxaliplatin for the indicated times. Flow cytometry was used to detect fluorescence intensity to measure MMP, using rhodamine 123 fluorescent dye (G). Cytochrome c release was analyzed by cytoplasmic fraction. MnSOD was used as a mitochondrial fraction marker (H). I The cancer cell lines were transfected with control siRNA or cathepsin K siRNA and were treated with 25 μM oxaliplatin for 24 h. Apoptosis and protein expression were measured by flow cytometry (A–C, F, and I) and western blotting (A, B, F, H and I). Cell morphology was assessed using a microscope; scale bar: 50 µm (C). The values in the graphs AG, and I represent the mean ± SD of three independent experiments. *P < 0.01 compared to the control. #P < 0.01 compared to the ODN-plus-oxaliplatin combination. **P < 0.01 compared to the cathepsin K siRNA-transfected cells treated with oxaliplatin.